Jamie Kendall & Alexandra Schulz, What First Amendment? FDA Remains Unfazed By Off-Label Communication Issues, Pharm Exec.Com (Mar. 7, 2017),
Perhaps it was wishful thinking. Did the industry believe that the FDA would wave its wand and provide clarity on the topic of manufacturer communications regarding unapproved uses of approved or cleared medical products? Apparently, yes.
Read full article here: http://www.pharmexec.com/what-first-amendment-fda-remains-unfazed-label-communication-issues.